





24 Easy to swallow tablets

SB

Panadol®



Extra



Extra effective pain relief
Reduces fever • Gentle on stomachs

24 Easy to swallow tablets

SB

Panadol®



Extra



Extra effective pain relief
Reduces fever • Gentle on stomachs



Lipitor™ 20 mg
ATORVASTATIN

30 filmcoated tablets each
containing atorvastatin 20 mg

 **PARKE-DAVIS**



Lipitor™ 20 mg
ATORVASTATIN

30 filmcoated tablets each
containing atorvastatin 20 mg

 **PARKE-DAVIS**





Analyse : july 2008

AUTHENTICITY EVALUATION ANALYTICAL TESTING REPORT

Impacted Product:	Lipitor.
Samples:	<p>One Purported Middle East Market Format Lipitor 10mg IFC Containing One PIL and Three Blisters Each Containing Ten Purported Lipitor 10mg Tablets.</p> <p>One Purported Middle East Market Format Lipitor 20mg IFC Containing One PIL and Three Blisters Each Containing Ten Purported Lipitor 20mg Tablets.</p> <p>One Purported Middle East Market Format Lipitor 20mg IFC Containing One PIL.</p> <p>Two Purported Lipitor 20mg Blisters Each Containing Ten Purported Lipitor 20mg Tablets – Obtained from Pharmacists in Lebanon.</p>
Pfizer Internal Identifications:	<p>11120-4749-D10623105</p> <p>11120-4750-D10623106</p> <p>11120-4751-D10623107</p> <p>11120-4752-D10623104</p>
Agency/ Submitting Country:	Toufic Bou Younes, Pfizer Market Manager – Sales Lebanon/ Pfizer Global Security London/ Lebanon.
Conclusions:	<p><u>D10623105 and D10623106: Counterfeit Drug Product Tablets and Middle East Market-Format Packaging - Tablets Contain Lovastatin Drug Substance.</u></p> <p><u>D10623107: Counterfeit Drug Product Tablets and Middle East Market-Format Packaging – Tablets Contain Metronidazole Drug Substance.</u></p> <p><u>D10623104: Counterfeit Middle East Market-Format Packaging.</u></p>

Chain of Custody Information:

Received by (name):	Wendy Greenall.
Date Received:	17-Jun-08, Pfizer Internal Mail, EB's D10623105, D10623106, D10623107 and D10623104.
Receiving Laboratory:	EMA Counterfeit Testing Laboratories, Quality Operations, Sandwich, Pfizer LTD, ENGLAND.
Sample from (name/dept):	Nikki Reffell (Pfizer Global Security, LONDON)
Date(s) of Testing	09-Jul-08, 10-Jul-08 and 14-Jul-08

Description of sample, visual evaluation, and spectroscopic comparison:

Xanax™

Tablets



Pharmacia
& Upjohn

0.5 mg

Alprazolam



30 Tablets
FOR ORAL USE

Xanax™

Tablets



Pharmacia
& Upjohn

0.5 mg

Alprazolam



30 Tablets



Cialis[®]

tadalafil
tadalafil
tadalafil
20 mg

Lilly

Mfg./Exp.:

alis[®]

tadalafil
tadalafil
tadalafil
20 mg

Lilly

Mfg./Exp.:

NOM DU MÉDICAMENT	FABRICANT	NUMÉRO DE LOT	PRODUCTION EXPIR.	QUANTITÉ REQUISITIONNÉE
1 MAXIPIME 1G IM/IV 1 AMP INJ	BMS ITALY FOR BMS USA	5K03681	03/2005 - 03/2008	425
2 ROCEPHINE 1G IV + 1 AMP SOLVANT 10ML	F. HOFFMANN-LAROCHE SWITZERLAND	B2858 B1160(11/04)	01/2004 (B2858)	195
3 MARCAINE HEAVY 0.5% 5X4ML INJ	ASTRA ZENACA UK LTD	GL2391	11/2008	38
4 TAZOCIN 4G/0.5G POWDER FOR IV INF.	WYETH LEDERLE ITALY	AB8Y/11 ABES/11	12/2005 - 12/2007 02/2006 - 02/2008	222
5 DIFLUCAN 2MG/ML IV 50ML	PFIZER FRANCE	4086405	07/2004 - 07/2009	46
6 TAXOTERE 20MG + SOLVANT IV	AVENTIS FRANCE AVENTIS UK	D5G010	11/2007	14
7 TAXOTERE 80MG + SOLVANT IV	AVENTIS PHARMA UK	D5E901	06/2005 - 06/2007	1
8 GEMZAR 200MG POWDER IV 1 AMP INJ	LILLY FRANCE	FF5V06E	09/2005 - 08/2008	50
9 GEMZAR 1G POWDER IV 1 AMP INJ	LILLY FRANCE	5799B FF5D03B	06/2005 - 07/2008 04/2005 - 05/2008	37
10 MARCAINE SPINAL HEAVY 0.5% 5X4ML INJ	ASTRA ZENACA TURKEY UNDER LICENSE FROM UK	455042	12/2005 - 12/2008	41
11 CISPLATIN EBEWE 50MG 1 AMP 100ML	EBEWE AUSTRIA	505014	07/2005 - 06/2007	13
12 ZOMETA 4MG POLIDRE + SOLVANT INJ	NOVARTIS PHARMA SUISSE	F07600	07/2004 - 07/2007	8
13 CAMPTO 40MG 1 AMP INJ 12ML	AVENTIS PHARMA TURKEY	D4C276	08/2004 - 08/2007	11
14 MARTHERA 100MG 2 AMP INJ 10ML	F. HOFFMANN-LA ROCHE SWITZERLAND	C0024	10/2005 - 03/2008	6
15 MARTHERA 500MG 1 AMP INJ 50ML	F. HOFFMANN-LA ROCHE SWITZERLAND	B2014	04/2005 - 07/2007	1
16 MAXIPIME 2G IV 1 AMP INJ	BMS ITALY FOR BMS USA	4K85229	04/2004 - 09/2007	2
17 TAXOL 100MG (8MG/ML) 1 AMP INJ	PACKED BY BMS ITALY FOR BMS USA	5K03209	09/2005 - 09/2007	27
18 CAMPTO 500MG 1 AMP INJ 5ML	PFIZER BUDAPEST	05F635	05/2005 - 05/2008	1
19 CLAFORAN 1G IV 1 AMP INJ	PATHEON UK	125176	12/2005 - 12/2007	19
20 ELOXATINE 50MG 1 FLACON INJ	SANOFI WINTHROP FRANCE	536 (EXT) 1022 (INT)	06/2005 - 06/2008 00/2005 - 00/2005	3

NOM DU MÉDICAMENT	FABRICANT	NUMÉRO DE LOT	PRODUCTION EXPIR.	QUANTITÉ REQUISITIONNÉE
21 CARBOPLATINE EBEWE 450MG 1 AMP INJ	EBEWE AUSTRIA	509049	11/2005 - 10/2007	2
22 SOMATOSTATIN 3MG IV 1 AMP + SOLVANT	UCB BELGIUM	3524 PDRE 9682 SOLV.	10/2004 - 10/2007 08/2010	2
23 ZOFRAN 8MG 5 AMP INJ 4ML	PACKED BY GLAXO EGYPT FOR GLAXO UK	53589	10/2005 - 07/2008	1
24 ZINACEF 750MG 5 AMP INJ	GLAXO SAUDI ARABIA	K5018	11/2005 - 11/2008	5
25 TIENAM 500MG 1 FLACON INJ	MSD NETHERLANDS	NE 02860	05/2006 - 05/2008	32
26 TAXOTERE 80MG + SOLVANT IV	MARKETING AUTHORIZ. HOLDER AVENTIS	D5H117	11/2008	3
27 TAXOTERE 20MG + SOLVANT IV	MARKETING AUTHORIZ. HOLDER AVENTIS	D5G815	11/2007	7
28 SOLU-MEDROL 125MG 1 AMP INJ	PFIZER HELLAS	5170	12/2008	400
29 CAMPTO 100MG 1 AMP INJ	RHONE-POULENC RORER	D6C122	11/2005 - 11/2008	11
30 MARCAINE HEAVY 0.5% 5X4ML INJ	ASTRA ZENECA	0455045	03/2006 - 03/2009	
31 HUMAN ALBUMIN 20% 1 FLACON INJ	BIOTEST GERMANY	A137175	04/2005 - 04/2008	121
32 HUMAN ALBUMIN 20% 1 FLACON INJ	OCTAPHARMA AUSTRIA	4470776334	11/2004 - 11/2007	167
33 GEMZAR 1G POWDER IV 1 AMP INJ	LILLY ISTAMBUL	68208A	02/2006 - 02/2009	
34 TAXOL 300MG (6MG/ML) 1 AMP INJ 50ML	BMS CARIBBEAN USA	5K01800 6C12143	08/2005 - 08/2007 12/2005 - 12/2007	6
35 TAXOL 100MG (6MG/ML) 1 AMP INJ	BMS ISTAMBUL	6C19538	03/2006 - 03/2008	
36 ELOXATINE 100MG 1 FLACON INJ	SANOFI WINTHROP FRANCE	2079	02/2006 - 02/2008	2
37 SERO-TEST HIV 50UI	GREEN CROSS CORP. KOREA	08T5192	11/2005 - 01/2009	14
38 ANTI-D (RHO) HUMAN IMMUNOGLOBULINE 2ML INJ	ERON	45698	10/2008	45
39 NAVELBINE 50MG/5ML INJ	PIERRE FABRE	AQ5044	09/2004 - 09/2007	8
40 TET HUMAN 1 AMP 250UI	BELLON FRANCE	E8521	05/2005 - 05/2008	55

MabThera®

Rituximab

500 mg/50ml

1 vial of 50 ml of concentrate
for solution for infusion



Roche

To Whom it May Concern

Basel, 16 March 2007

Suspected Counterfeit of MabThera (rituximab) 100mg/ml Package

Roche reference: #30908

To whom it may concern


A suspected counterfeit package of "MabThera" was confiscated by the Lebanese Ministry of Health who requested that Roche analyse the packaging and vials to determine whether they are counterfeit.

Upon investigation, the packaging has proved to be counterfeit. The analysis of the vials suspected not to be "MabThera" provided the following results:

- The vials do not contain rituximab, which is the active ingredient of MabThera®
- The likely content has been identified as water
- No other active ingredients were detected
- Endotoxins were within specifications for MabThera (< 0.3/ml)

It can be concluded that the vials analysed are counterfeit of MabThera®.

Yours sincerely,


Dimitris Papadopoulos
Acting Lifecycle Leader,
MabThera Oncology


Dirk-Jan Paans
International Business Leader,
MabThera in RA

Avastin™

Bevacizumab

400 mg/16 ml 400

1 vial of 16 ml of
concentrate for solution
for infusion



Avastin®

Bevacizumab

400 mg/16 ml 400

1 vial of 16 ml of
concentrate for solution
for infusion





To Whom It May Concern

Basel, 11th August 2008
Avastin Vials 400mg : B3219
Counterfeit in Jordan

Dear Sir,
Dear Madam,

F. Hoffmann-La Roche Ltd, Marketing Authorisation Holder of Avastin, is confirming one case of counterfeit Avastin vials 400 mg received from Jordan on March 28, 2008. The detected counterfeit concerns the packaging presentation of batch B3219, item code 3619001, expiry date 11.2009.

Roche Basel made no deliveries with goods MFD/EXP 11.2007/ 11.2009 but only with MFD 11.2006, EXP 11.2008.

The outer packaging (folding box, leaflet, vial and partition wall) are noticeably different from the samples retained by Roche for comparison. Therefore QA Packaging Material concluded that the Avastin 400 mg sample sent by Roche Jordan is a counterfeit.

In addition there were noticeable differences for the vial's outer dimensions, the stopper color and the target ring pattern to the standard.

Analysis of the vial contents have been conducted. The analyses of the suspected counterfeit (complaint TW#56364) revealed that the vial contains Polysorbate 20, Ethanol and Acetate (all in the low mM or μ M range), negligible amounts of protein, and no trehalose (excipient in the Avastin formulation). While Polysorbate 20 is an excipient in the Avastin formulation, Ethanol and Acetate are not included in the Avastin formulation, as demonstrated for a retained sample of Avastin B3219 used as a reference. The analyses confirm without doubt that the content is also a counterfeit.

Microbiological testing was performed and showed a bioburden of >200 cfu/ml. With *Citrobacter braakii*, *Raoultella ornithimolytica*, *Citrobacter freundii* and members of the family of Xanthomonadaceae a number of different aerobic microorganisms were identified with *Raoultella ornithimolytica* classified as critical. Bacterial endotoxins exceeded the registered specification more than 100-fold (251 EU/ml).

PL-LB 0005 Batch 1922

Different
font




Different
font

Plant packaging material 76626 in data base




3.3 Tablet's appearance

The sample case PL-LB 0010 has different engraving compared to the sample batch 1932.




Assay chromatographic profiles:

Standard solution:



Sample PL- LB 0005 solution:



صحتك ما بتتمن... إنتبه للأصلي



هذه العلامة تضمن أن الدواء يحترم
السلسلة المسؤولة من التصنيع مروراً
بمستورد مرخص وصولاً إلى الصيدلي.



هذه علامة وضعت خصيصاً
للاشارة أن ال Plavix هو أصلي
وليس مقلد أو مزور.



للتأكد من أن علبة ال Plavix هي أصلية
الرجاء التأكد من مكان الفتححة المزم.



sanofi aventis
Because health matters

Plavix
Clopidogrel 75mg

"The product item is the King of Security"

3095614 UN 0001
EXP 10 2008
B1034
MFD10 2006

3095614 UN 0001
EXP 11 2008
B1030
MFD11 2008
Neupogen®



To Whom it May Concern

Basel, 22 August 2007

Re.: Identity Test of Suspected Counterfeit Neupogen vial 0.3mg/1ml – ref. TW# 39617

Dear Sirs,

Roche was informed about several cases of side effects occurring with patients after administration of Neupogen at Ghassan Hammoud Hospital in Saida-South Lebanon. Roche representative office in Lebanon suspected that this sample could be a counterfeit after its visual observation.

The complaint sample consists of one vial of Neupogen® with strength 30 Mio U/E. The concerned batch number is B1030. The MFD and expiry date are 11/2008 and 11/2006, respectively.

Statement QA Packaging Material:

The internal investigation revealed the following differences in comparison to the original:

- Printing mistake in the ingredients (“acetasm” instead of “acetas”), manufacturing and expiry date (“MFD 10 2008” and “EXP 11 2006”).
- Colour variation of metallic and plastic seal (blue/silver instead of blue/gold).

Chemical analysis:

Based on analysis the complaint sample doesn't contain any granulocyte-colony stimulating factor and was therefore characterized as non Neupogen®.

Conclusion:

It can be concluded that the analyzed vial is counterfeit of Neupogen®.

Yours sincerely,

F. Hoffmann - La Roche Ltd.


Urs Foelml
Head of Mature Products

Urs Salzmann
International Portfolio Business Manager


Plan d'action-phase 1

- Conférence de presse annonçant la 1^{ère} Campagne Nationale pour la lutte contre les médicaments contrefaits. (6/8/2008)
- Billboards (823)
- Radio, TV interview, spots TV.
- Journaux
- Séminaires (pour tous les acteurs)
- Posters (facultés, officines, hôpitaux)
- Guide (médecins, pharmaciens, magistrats)
- Flyers (pour patients)
- Sacs (pour patients)
- Call Center
- CMC

**COUNTERFEIT DRUGS
KILL!**



counterfeit drugs are silent killers
distributed by criminals
YOU ARE THE PATIENT. IT IS YOUR RESPONSIBILITY TO ASK
YOUR PHARMACIST... YOUR BEST GUARANTEE



**Combattre la contrefaçon
des médicaments:
1^{ère} campagne nationale**

CIOPF

Présenté par
Dr Ziad NASSOUR
Vice-Président de la CIOPF
Relève la contrefaçon à la CIOPF
Ancien Président de l'Ordre des Pharmaciens du Liban

Conférence de Presse
le mardi 4 août 2014

**LE MÉDICAMENT CONTREFAIT
TUE!**



Le médicament contrefait est un tueur s'il
est distribué par des criminels
VOUS ÊTES LE PATIENT
LE PHARMACIEN EST VOTRE MEILLEUR GARANT






الجمهورية اللبنانية
وزارة الصحة العامة

لجنة صيدلة لبنان

Egyptian Pharmaceutical Regulatory Board
EPRB

**COUNTERFEIT DRUGS
KILL!**

الحملة الوطنية الاولى للتوعية ومكافحة الادوية المزورة / المقلدة
الاربعاء ٦ آب ٢٠٠٨
فندق الحيتور



الجمهورية اللبنانية
وزارة الصحة العامة

لجنة صيدلة لبنان

Egyptian Pharmaceutical Regulatory Board
EPRB